Halozyme Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial statements are unaudited. Amounts below are in U.S. dollars; financial figures are rounded to millions unless stated otherwise.
Business context
Halozyme licenses its ENHANZE drug-delivery technology, based on rHuPH20, to biopharmaceutical partners and earns royalties, milestone payments, and product revenue. It also sells proprietary products, including Hylenex and XYOSTED, and supplies partnered devices and bulk rHuPH20. The company reports one operating segment.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $195.9M | $162.1M | +20.8% |
| Operating income | $95.5M | $53.8M | +77.6% |
| Net income | $76.8M | $39.6M | +93.9% |
| Diluted EPS | $0.60 | $0.29 | +106.9% |
| Operating cash flow | $129.4M | $87.0M | +$42.5M |
- Revenue mix: Royalties were $120.6M, up 21%; net product sales were $58.6M, down 4%; collaborative-agreement revenue was $16.7M versus $1.7M. The collaborative-agreement increase included $14.0M of event-based development and regulatory milestone revenue.
- Product sales detail: Proprietary product sales rose 26% to $35.3M; bulk rHuPH20 sales fell 52% to $10.5M, primarily due to shipment timing; partnered device sales increased 19% to $12.8M.
- Margins and expenses: Operating margin was approximately 48.8%, versus 33.2% a year earlier. Cost of sales declined 19% to $28.3M, while R&D increased 6% to $19.1M and SG&A declined 6% to $35.1M. Net margin was approximately 39.2%, versus 24.4%.
- Cash flow and investments: Operating cash flow was $129.4M. Investing activities used $82.7M, mainly reflecting net purchases of marketable securities; financing activities used $0.5M. Cash and cash equivalents increased to $164.6M from $118.4M.
- Liquidity: Cash, cash equivalents, and marketable securities totaled $463.5M at quarter-end. Current assets were $873.6M and current liabilities $131.6M. Management stated available liquidity should fund operations for at least the next 12 months.
- Debt: Long-term debt, net, was $1.501B; convertible-note principal totaled $1.525B, with notes due in 2027 and 2028. The $575M revolving facility was undrawn. Management reported compliance with debt covenants and no material adverse change in business, operations, or financial condition.
- Share count and equity: Weighted-average diluted shares fell to 128.9M from 137.9M. Stockholders’ equity was $177.8M at quarter-end, up from $83.8M at year-end 2023.
Material changes and management commentary
- Royalty growth was attributed primarily to continued DARZALEX SC and Phesgo sales growth and the launch of VYVGART; this was partly offset by lower Herceptin SC and MabThera SC sales. Halozyme cited IV biosimilar pricing pressure on mature products and a March 2024 royalty-rate reduction for certain DARZALEX SC sales outside the U.S.
- Management expects royalty revenue to continue growing, with growth from 2020 and 2023 partner-product launches partly offset by biosimilar-related pricing effects. Proprietary product sales are expected to grow over time; bulk rHuPH20 and partnered-device sales may fluctuate with partner demand. Collaborative-agreement revenue is expected to vary with partner milestones and new agreements.
- Management estimated a 2024 annual effective tax rate of approximately 20%. Q1 income tax expense was $19.2M, or about 20% of pretax income.
- The company reported $463.5M in cash, equivalents, and marketable securities and said it may use existing resources, collaboration revenue, and future financing transactions to fund operations and other corporate purposes.
- The Board authorized a new $750M share-repurchase program in February 2024. The prior $750M program was expected to be completed in Q2 2024.
Outlook, risks, and unusual items
- No numerical full-year revenue or earnings guidance is provided in the filing. Outlook statements are forward-looking and subject to risks and uncertainties.
- Revenue depends substantially on partner product sales, development progress, regulatory decisions, and milestone achievement. Partner demand also affects bulk enzyme and device sales. The filing notes that one ViiV cabotegravir SC program was no longer being pursued for long-term dosing.
- Q1 collaborative-agreement revenue included a $14.0M milestone-related item, making that revenue stream potentially uneven between periods. The company also recognizes royalties using estimates before final partner reports are received.
- Post-quarter developments included BMS’s May acceptance of the Opdivo SC BLA, which triggered a $15.0M milestone, and other partner regulatory updates. These are subsequent events, not Q1 revenue.
- Market risks include interest-rate effects on investment values and foreign-exchange fluctuations on Swiss-franc royalty revenue; the company uses cash-flow hedges and reported all hedges were highly effective. Management reported no material change in market risks or risk factors during the quarter.
- The company was not party to legal proceedings that management believed would have a material adverse effect. Disclosure controls were assessed as effective, with no significant changes in internal control over financial reporting reported.
Important facts for investors to verify
- How much royalty growth is sustained by partner-product sales versus affected by biosimilars and royalty-rate reductions.
- Whether the Q1 milestone revenue and post-quarter milestones are repeatable, and how partner regulatory and commercial progress develops.
- Whether bulk rHuPH20 shipment timing and inventory growth—inventory rose to $168.5M from $127.6M—affect future cash conversion.
- Debt repayment and conversion terms for the 2027 and 2028 notes, and the pace and funding of the new $750M repurchase program.
- Progress and commercial performance of proprietary products, particularly XYOSTED, and the partner programs supporting future royalties.